English
Deutsch
Français
Nederlands
Español
Reset. Heal. Grow.
Is Ibogaine a Mindfulness Pill? What the Iboga Experience Really Teaches
Someone asked me last year, half-joking, whether iboga was basically a mindfulness pill. The kind of thing you swallow when sitting on a cushion for ten years feels like too long a wait. I laughed. Then I thought about it for a week. Because the question, underneath the flippancy, points at something real. People who've sat with iboga — or its pharmaceutical cousin ibogaine — often describe an experience that sounds suspiciously close to what long-term meditators report: an unflinching look at their own conditioning, the loosening of compulsive patterns, a strange and uncomfortable clarity about who they've been. So is it a shortcut? Is it cheating? Is it even the same thing? I want to talk through this honestly, because I think the answer matters — especially if you're someone weighing whether to fly to Mexico or Costa Rica or Portugal and hand yourself over to a facilitator with a root bark and a stethoscope. Mindfulness, in the way it's taught now, usually means non-judgmental awareness of the present moment. You notice what's happening — thoughts, sensations, emotions — without grabbing at it or pushing it away. Done consistently over years, it tends to produce people who are less reactive, more present, better at noticing the gap between stimulus and response. That's the public-facing version. The deeper claim of contemplative traditions is bigger: that sustained practice reveals something about the nature of the self. That the “you” running the show is more constructed and more porous than it feels. Buddhist teachers have been pointing at this for two and a half millennia. It's not a productivity hack. It's a slow-motion ontological audit. Here's where iboga gets interesting. Because whatever else it does, it forces an audit. It just does it in fourteen hours instead of fourteen years. Iboga is the root bark of Tabernanthe iboga, a shrub native to Central Africa, used ceremonially for centuries by the Bwiti tradition in Gabon. Ibogaine is the principal alkaloid, extracted and used in clinical and retreat settings — most famously as a treatment for opioid and stimulant addiction. The two are related but not identical experiences. The whole-root ceremony tends to feel more textured and more guided by the plant's own logic; ibogaine in a clinic setting can feel more pharmacological, more medical. Either way, the experience is long. We're talking 12 to 36 hours of altered consciousness, with the most intense phase lasting maybe eight to twelve. People often describe two distinct stages. The first is sometimes called the “visionary” phase — a flood of memories, images, and what feels like a structured review of one's life. Not random imagery. Specific scenes, specific people, specific moments where you made a choice that set a pattern in motion. The second phase is quieter and stranger. The visions fade and you're left lying in the dark, mostly awake, watching your own mind work without the usual filters. This is the part that participants frequently describe as “meditation-like,” though it's a meditation you didn't sign up for and can't end early. Yes and no. Let me explain. The yes: iboga absolutely does produce states of detached, observational awareness. People come out of ceremonies describing days or weeks of unusual clarity — they can see their habitual reactions before they fire, they notice cravings without acting on them, they catch themselves in the middle of an old story and just… don't finish telling it. That's recognizably what mindfulness practice is supposed to deliver. There's emerging research suggesting ibogaine affects neuroplasticity in ways that may temporarily increase this kind of metacognitive capacity. The no: a pill that gives you the view for a month is not the same as a practice that gives you the legs to keep walking. Plenty of people have profound iboga experiences and slide right back into the patterns they thought they'd seen through. The experience hands you a map. It doesn't hand you the discipline to actually use it. This, by the way, is where iboga differs sharply from ayahuasca or psilocybin in the cultural conversation. Iboga isn't really sold as a journey. It's sold as a confrontation — particularly for people struggling with addiction. The marketing language around it is less “heart-opening” and more “interrupting a death spiral.” Which is closer to the truth. The reason ibogaine has built a reputation outside the broader psychedelic conversation is its effect on opioid dependence. People with heroin or fentanyl addictions report walking out of an ibogaine treatment with their withdrawal symptoms gone and their cravings dramatically reduced. This isn't a small thing. It's the closest thing the addiction field has to a chemical reset button — and that's why underground and offshore clinics have been running treatments for decades despite ibogaine being a Schedule I substance in the United States. But — and this is critical — ibogaine is not safe in the casual way some other plant medicines can be approached. It's cardiotoxic. It can cause fatal arrhythmias in people with undiagnosed heart conditions or certain medication interactions. Reputable clinics require EKGs, bloodwork, and medical supervision throughout. If you're researching ibogaine and a provider doesn't mention any of this, walk away. I mean it. A few things worth knowing if you're considering it: In the Amazonian traditions, ayahuasca isn't the only “master plant” — there's a whole pharmacopoeia of teachers, each said to offer a particular kind of instruction. Iboga sits in a parallel category from a different continent. The Bwiti tradition treats it not as a substance but as a teacher, an ancestor, something you enter into relationship with. That framing matters because it pushes back against the “mindfulness pill” idea. You don't take a master plant. You consult one. And the consultation, if you're paying attention, includes homework. The visions show you what's broken. The integration phase is when you decide whether to actually fix it. People who treat iboga as a one-shot fix tend to be disappointed. People who treat it as the beginning of a longer practice — therapy, meditation, lifestyle change, community — tend to be the ones whose lives actually shift. If you're researching iboga or ibogaine, start with brutal honesty about why. Are you looking for addiction recovery? A spiritual experience? Relief from depression that hasn't responded to anything else? Each of those points you toward different providers, different settings, different price points. A medical ibogaine clinic in Mexico is a very different proposition from a Bwiti-influenced ceremony in Costa Rica or Portugal. Both can be legitimate. Neither is interchangeable. Be skeptical of any provider promising transformation. Be more skeptical of one promising it without medical screening. And give yourself a serious think about what you'll do for the six months after — because that's the part that determines whether the experience becomes a turning point or a story you tell at parties. For readers wanting to take this further, a range of vetted ibogaine and plant-medicine retreats can be browsed on our marketplace here. Whether iboga is a mindfulness pill or not, it's a serious tool — and the people who get the most out of it tend to be the ones who treat it that way from the first phone call.
Psychedelic Water Review: Does Kava Really Replace Your Evening Drink?
A friend of mine cracked open one of these cans at a backyard dinner last summer and someone immediately asked if she was tripping. She wasn’t. She was drinking what looked like a hard seltzer, was called Psychedelic Water, and contained roughly zero psychedelics. The name does a lot of heavy lifting — some of it useful, some of it misleading. I spent about a month using it the way the marketing suggests: as the thing in my hand at gatherings where everyone else was reaching for a margarita. I’m not strictly sober, I just have terrible hangovers and a low tolerance for the slow social erosion that comes with regular drinking. So this counted as a real experiment, not a stunt. Here’s what I learned about the drink, the ingredients, and the broader trend it rides on — including how it overlaps (and doesn’t) with the actual world of psychedelics and plant medicine. The headline ingredient is kava — a root from the South Pacific that islanders have used in social and ceremonial settings for centuries. Traditional kava is prepared by pounding or grinding the root and mixing it with water until you have something resembling muddy dishwater that tastes, frankly, the way it looks. The canned version is a much gentler product: kava extract, damiana leaf (a mild relaxant with a long history in Central America), green-tea extract for a small caffeine lift, and flavoring. Four flavors are in rotation — hibiscus lime, blackberry yuzu, oolong orange blossom, and prickly pear. Prickly pear is the one to start with. What kava does in the body is sedative-adjacent. It binds to GABA receptors, which is the same general pathway alcohol and benzodiazepines use, although kava is far gentler. You feel a softening of the edges. A loosening in the shoulders. Conversation feels easier without the sloppy disinhibition booze gives you. The National Institutes of Health notes that kava supplements have shown a small effect on reducing anxiety in clinical studies — modest, but real. One thing worth flagging up front: kava has been linked in rare cases to liver injury, especially when used heavily or combined with alcohol or certain medications. If you’re on prescription meds, drink regularly, or have any liver concerns, talk to a doctor before making this a habit. The occasional can at a dinner party is a different beast than daily use. Let’s clear up the obvious confusion first. Psychedelic Water is not psychedelic. There is no LSD, no psilocybin, no DMT, no mescaline. You will not see geometric patterns. You will not have an ego-dissolution experience in your kitchen. The name is a marketing choice — provocative, memorable, and arguably useful in the way it nudges the word “psychedelic” into ordinary supermarket vocabulary, but the can itself is closer to a fancy herbal tea than to anything you’d find at an ayahuasca retreat. What it actually feels like, for me, was a soft 20-minute onset of mild calm. A faint tingle on the tongue (kava does that — it’s a quirk of the active compounds called kavalactones). A small lift in mood that didn’t spike or crash. After two cans across an evening I felt loose-jawed and content. After three I felt slightly queasy and had a dull stomach ache, so I’d say two is the practical ceiling. The most useful comparison I can give: it sits somewhere between chamomile tea and a single glass of wine on the relaxation spectrum, minus the next-day fog. I slept well. I woke up sharp. I did not text anyone something I regretted. By the modest standards of a Tuesday night, that’s a win. Nonalcoholic-beverage sales jumped roughly a third year-over-year a couple of years back, and the curve has kept climbing since. The category that used to mean O’Doul’s and grape juice now includes adaptogenic sodas, hemp-derived seltzers, functional mushroom blends, and a whole subgenre of kava drinks. Psychedelic Water is one of the louder voices in that crowd, partly because of TikTok and partly because of the name. The motivations behind sober-curious living are more varied than the wellness narrative suggests. Yes, some people are quitting for health. But just as many cite productivity, mental clarity, sleep quality, and the simple math of not wanting to feel rotten on Saturday morning. Younger drinkers are also doing it for cost — alcohol is expensive — and for the fact that they’ve grown up watching the long-term damage it does to the people around them. That last one matters more than people admit. Alcohol is a pretty effective short-term anesthetic. Take it away and a lot of stuff surfaces — restlessness, sadness, the patterns you’ve been numbing for years. Some people find that uncomfortable and circle back. Others find it’s the doorway they didn’t know they were looking for. Here’s where it gets interesting for anyone who lands on a drink like this and starts wondering what else is out there. Kava is, in the broadest sense, a plant medicine. It’s a botanical with psychoactive properties used ceremonially by an indigenous culture for generations. That puts it in the same loose family as ayahuasca, San Pedro, peyote, and the other master plants — but the family is very, very loose. Kava sedates. Ayahuasca rearranges your sense of reality for six hours and shows you the contents of your own mind. They are not the same tool. I’ve sat in a number of ayahuasca ceremonies and interviewed facilitators across Peru, Costa Rica, and the Netherlands. The thing readers most often miss is that the “psychedelic” part of psychedelics isn’t about visuals or recreation — it’s about a temporary suspension of the usual mental machinery that lets you see your patterns, your trauma, your addiction, your grief, with unusual clarity. That’s why these medicines have become a serious conversation in addiction recovery, depression treatment, and PTSD therapy. Compounds like psilocybin and ibogaine are now in late-stage clinical trials for exactly those uses. A canned kava drink will not do any of that. What it might do, honestly and usefully, is start a conversation. If you’re someone who picks up a can called Psychedelic Water at a dinner party and finds yourself curious — really curious — about what the word actually means, that curiosity is worth following. Read about the Indigenous traditions. Read the Johns Hopkins research. Talk to people who’ve done the work. Don’t confuse a beverage with a ceremony. If you’re looking for a smarter thing to hold at a party, or a wind-down drink that won’t cost you Sunday morning, this category is worth exploring and Psychedelic Water is a reasonable entry point. Go in with realistic expectations. You’re buying a mild herbal relaxant in a stylish can, not a portal to anywhere. Pay attention to how your body responds, don’t mix it with alcohol or sedatives, and skip it entirely if you’re pregnant, on liver-sensitive meds, or drinking heavily already. And if the experiment leaves you genuinely interested in what plant medicines can do at the deeper end — addiction work, trauma work, the kind of inner inventory that actually changes a life — there’s a much larger world waiting. A growing range of ayahuasca, psilocybin, and other plant-medicine retreats can be browsed on our marketplace here, with facilitators and traditions worth taking seriously. Start with the can if you want. Just know that the can is the beginning of the question, not the answer.
Shamanism, Plant Medicine, and the Ancient Science of Altered States
Long before anyone called it neuroscience or wrote a peer-reviewed paper about psilocybin, people in nearly every corner of the planet were already doing the work. Sitting in caves. Drumming for hours. Drinking bitter brews made from vines and bark. Coming back changed. This is the strange, persistent fact at the heart of shamanism — that humans, separated by oceans and millennia, kept arriving at the same techniques for entering altered states. Rhythm. Fasting. Sacred plants. Movement. And then they kept using those states for the same purposes: healing the sick, settling communal disputes, finding game, mapping the unseen, and locating the human inside a larger living web. For anyone considering an ayahuasca retreat or any kind of psychedelic ceremony today, this older lineage matters. It's the soil the modern conversation grew out of. Anthropologists have been arguing for a century about whether ‘shamanism' is one thing or many. The honest answer is: both. Siberian healers, Amazonian curanderos, southern African sangomas, and Mongolian buryat shamans don't share a religion. They share a toolkit. Trance. Spirit communication. Healing through ritual. A sense that the natural world is alive and conversational. What's striking is how often the toolkit overlaps in oddly specific ways. Hand drums and rattles. Animal mimicry in dance. Plant preparations passed down through apprenticeships that can last a decade. The shaman as a kind of community generalist — part doctor, part priest, part field botanist, part therapist, part diplomat with the more-than-human. Researchers like Michael Winkelman have argued that shamanism is essentially a neurotheology — a set of practices our species figured out, by trial and error, for working with the human nervous system. Different cultures, similar machinery, similar results. The drum is the most underrated technology in human history. Rock art from over ten thousand years ago shows figures holding frame drums and rattling staffs. Modern EEG studies have found that steady percussion in roughly the 4–7 Hz range nudges the brain toward theta-wave activity — the same territory where vivid imagery, dream-logic, and creative insight tend to live. That's not mystical. That's measurable. Rhythmic auditory driving, as researchers call it, entrains neural oscillations. Combine it with controlled hyperventilation, fasting, sleep restriction, and hours of repetitive movement, and you have a reliable recipe for getting the ordinary mind to step aside. Add a sacred plant on top of that, and you're working with something even more potent. Some of the oldest decorated caves in Europe — Lascaux, La Garma — turn out to have peak acoustic resonance right around 110–120 Hz, frequencies linked to altered consciousness in laboratory studies. The painters seem to have chosen these chambers deliberately. Firelight on painted animals, voices and drums bouncing off curved stone, hours of preparation. A multimedia immersion designed thousands of years before anyone had the word. Ayahuasca didn't appear in a clinical trial in 2015. It's been brewed in the western Amazon for at least four thousand years, possibly longer. Peyote use in what's now northern Mexico shows up in archaeological sites dating back roughly six thousand years. San Pedro cactus residues in Peru go back further still. The idea that psychedelics are a counterculture invention is, frankly, a little embarrassing once you look at the timeline. Traditional healers refer to these botanicals as master plants — teachers, not products. The framing matters. A master plant isn't a substance you consume to feel something; it's a being you enter into relationship with, usually after extensive preparation, dietary restriction, and apprenticeship. Curanderos in the Amazon will tell you the plant chooses you as much as you choose it. You can take or leave that metaphysically. Pragmatically, the framing tends to produce more careful, more integrated experiences. The ayahuasca brew itself is a piece of pharmacological brilliance. The vine Banisteriopsis caapi contains MAO-inhibitors. The leaves of Psychotria viridis contain DMT, which would otherwise be broken down in the gut before reaching the brain. Combine them, and the DMT becomes orally active. How an illiterate forest culture worked this out, from roughly 40,000 plant species in the Amazon basin, is one of those questions ethnobotanists shrug at and call ‘plant intelligence' or ‘the dreams told us,' depending on who you ask. The renewed scientific interest in psychedelics over the past two decades has, in many ways, confirmed what shamans have been saying for generations. Studies at Johns Hopkins, NYU, and Imperial College London have found that psilocybin and ayahuasca, used in supportive ceremonial-style settings, can produce lasting reductions in depression, treatment-resistant anxiety, and substance use disorders. Ibogaine has shown remarkable results for opioid addiction in clinical contexts — sometimes interrupting decades-long patterns in a single session. What's interesting is that the size of the therapeutic effect seems to correlate with the depth of what participants describe as the mystical experience itself. The science is essentially measuring the same thing the curanderos were pointing at: a profound shift in self-perception and meaning, followed — if integrated well — by changes in behavior. That last clause is the one most often glossed over in the breathless coverage. Plant medicine for addiction recovery, plant medicine for depression, plant medicine for trauma — these are real possibilities, but they live or die on what happens after the ceremony. Integration is the unglamorous part. The journaling, the therapy sessions, the changed routines, the awkward conversations. Without it, even the most cinematic vision tends to fade like a dream you can't quite hold onto by lunchtime. One of the things that gets lost when shamanism is reduced to ‘ancient psychedelic therapy' is the worldview it sits inside. Animism — the perception that rivers, mountains, plants, and animals possess their own inner life — isn't a quaint primitive belief. It's a functioning ecological operating system. When the forest is full of persons rather than resources, you treat it differently. You take only what's needed. You ask permission. You give back. Traditional ecological knowledge, accumulated over generations of this kind of attentive reciprocity, has repeatedly turned out to be more accurate than outside experts assumed. Fire management in Australia. Forest gardening in the Amazon. Fisheries practices in the Pacific Northwest. The shamanic worldview produced not just visionary experiences but functional environmental science — encoded in story, song, and ritual rather than journals and graphs. This is part of why people walking out of an honest ayahuasca ceremony often describe feeling, for the first time, that the natural world isn't a backdrop. It's a participant. That shift, more than any single insight, is what tends to outlast the experience itself. If you're researching plant medicine because something in your life has hit a wall — addiction, depression, a grief you can't move through, a sense of being stuck inside your own head — knowing this longer history is useful for a few practical reasons. First, it should calibrate expectations. Shamanic cultures don't treat ceremony as a one-shot fix. They treat it as part of a longer arc that includes preparation, multiple sessions, dietary restriction, and a community to come home to. Retreats that promise transformation in a single weekend with no follow-up are missing most of the architecture that made these practices work for thousands of years. Second, it should sharpen your discernment when choosing a retreat. Reputable centers will talk openly about lineage — who their facilitators trained with, how long, in what tradition. They'll screen you medically and psychologically. They'll provide structured integration support afterward, not just a goodbye hug at the airport. They'll be honest about risks: difficult experiences, medication interactions, the real possibility that you come back rattled before you come back better. Third, it should remind you that the substance is a small part of the medicine. The container — the people, the place, the songs, the intention, the integration — does most of the actual work. A skilled facilitator working with mushrooms in a quiet farmhouse can produce more healing than a chaotic retreat charging four times the price. For readers who want to take this further, a curated range of ayahuasca and plant-medicine retreats can be browsed on our marketplace here. Whatever path you choose, take it slowly. The plants have been here for thousands of years. They'll still be here when you're ready.
Ibogaine Aftermath: Double Vision, Insomnia, and Body Temperature Swings Explained
Three days after a flood dose, you finally try to read something on your phone and the letters won't sit still. Sleep comes in 40-minute scraps. Your hands feel hot, your feet feel like ice, and your heart seems to be reporting from another time zone. Sound familiar? If you've recently sat with ibogaine — or you're researching what the recovery actually looks like before booking a retreat — this is the conversation nobody puts on the glossy brochure. Ibogaine is one of the most powerful tools in the plant medicine and psychedelic world for breaking addiction, particularly opioid dependence. It's also one of the most physiologically demanding. The aftermath can stretch out for weeks. Knowing what's normal, what's annoying, and what's a red flag matters. Most psychedelics clear your system in hours. Ibogaine doesn't play by those rules. The active alkaloid metabolizes into noribogaine, which binds to fat tissue and slowly releases back into circulation for days — sometimes weeks. That's part of what makes ibogaine so unusual for addiction work: the afterglow has a pharmacological tail. It's also why people report odd, lingering effects long after they assumed they'd be back to baseline. Noribogaine continues to nudge serotonin, dopamine, and opioid receptors. Your nervous system, meanwhile, has just been through something closer to a controlled crisis than a typical ceremony. The autonomic system — the one that runs your heartbeat, body temperature, digestion, and sleep — takes time to recalibrate. So when people show up in forums asking about double vision, insomnia, and thermoregulation chaos, they're not imagining things. These are documented post-ibogaine experiences. Across facilitator notes, harm-reduction guides, and the people I've talked with after their retreats, three after-effects come up over and over in the first one-to-four weeks: None of these are particularly fun. Most of them resolve on their own. But they're worth understanding so you can tell ordinary recovery from something that needs attention. During the ibogaine experience itself, eyes-closed visuals are part of the territory — the rapid film-reel of memories that the medicine is famous for. Afterwards, some people notice their eyes feel uncoordinated for days. Reading is hard. Phone screens blur. Driving feels unsafe. The mechanism is ataxia — a temporary disruption in the cerebellum's coordination of fine motor movement, including the muscles that aim your eyeballs. Ibogaine is famously ataxic during the acute phase (you'll have been walked to the bathroom by a facilitator for a reason), and residual cerebellar effects can hang around. Most people see this clear up within a week or two. If it's still happening at the four-to-six-week mark, that's the point to see a neurologist rather than another forum. This one surprises people. You'd think a medicine that knocks you flat for 24 hours would leave you ready to sleep for a month. Instead, the opposite often happens. Many people report two, three, even five days of almost no sleep after a flood dose, followed by weeks of choppy, fragmented rest. Part of this is noribogaine's stimulant-like profile slowly tapering off. Part of it is that opioid withdrawal — if that's why you came to ibogaine in the first place — has its own insomnia signature that doesn't fully resolve when the acute withdrawal does. And part of it is simply that your nervous system has been turned inside out and is still finding its footing. Practical things that help: keep caffeine to a minimum, get morning sunlight on your eyes, eat real meals at regular times, avoid heavy screens before bed, and accept that sleep will be weird for a while. Magnesium glycinate at night helps some people. Melatonin is hit-or-miss after ibogaine — some find it useful, others say it makes the dreams more intense than they want. Thermoregulation is run by your hypothalamus, which sits at the intersection of the endocrine and autonomic nervous systems. Both of those systems got rattled. So it's not strange that for a few weeks, your internal thermostat seems broken. People describe sweating through sheets, then shivering in a warm room twenty minutes later. Hands and feet that won't warm up. A face that flushes for no reason. Layered clothing is your friend. So is staying well hydrated with electrolytes — sodium, potassium, magnesium — because ibogaine is hard on minerals and the residual effects can show up as temperature swings. Most after-effects fade. Some don't, and a few are genuinely dangerous. The two that demand immediate medical attention are anything cardiac and anything that looks like a prolonged QT-interval issue. Ibogaine prolongs the QT interval, which means it can predispose the heart to a specific kind of arrhythmia called torsades de pointes. This is why reputable retreats screen for cardiac risk with an EKG, magnesium and potassium bloodwork, and a careful medication review before they'll give you a dose. The risk window for QT prolongation extends well past the ceremony itself — some studies suggest two weeks or more. Get medical care immediately if, in the weeks after ibogaine, you experience: The vast majority of people who do ibogaine in a properly screened, properly supervised setting come through without any of these. The minority who run into trouble usually skipped the screening — either because they treated at home with no medical backup, or because the operation they went to wasn't actually running the tests they claimed to. This is where the booking decision really lives, in my view. Anyone can hand you a capsule. What separates a credible ibogaine provider from a sketchy one is what happens before and what happens after. Things to ask before you put a deposit down: A serious operation will have answers ready. A sketchy one will get vague, defensive, or pivot to talking about how powerful the medicine is. The medicine is powerful. That's the point. It's also why the wrapper around the medicine — the screening, the supervision, the integration — matters more than the medicine itself. Here's the thing about ibogaine specifically, as compared with ayahuasca or psilocybin: the post-acute window stretches longer because of that fat-stored noribogaine slowly trickling back into your bloodstream. Many people describe two to six weeks of feeling unusually open, emotionally permeable, sometimes raw. The cravings for the substance you came to address may be remarkably quiet. Old emotional material may keep surfacing. This is the integration window. It's a gift if you use it. Therapy appointments scheduled in advance, a support group, a sober community, daily walks, journaling — the unglamorous infrastructure of recovery — work better in this window than at any other time. People who waste it tend to find the cravings creeping back. People who use it tend to describe ibogaine as the most useful single event in their recovery, even years later. If you're still researching whether this path is right for you, take your time. Read survivor accounts, read the harm-reduction literature, talk to people who've done it. For readers who want to take this further, a range of vetted ibogaine and plant-medicine retreats can be browsed on our marketplace here. The strange weeks after a flood dose aren't a sign that something went wrong. Usually they're a sign that something significant happened, and your body is still catching up. Treat that body kindly. Sleep when you can. Eat real food. Keep someone you trust in the loop. And if anything feels truly off — especially anything cardiac — don't tough it out. Get checked.
Psychedelics and Depression: What the Research Actually Shows About Plant Medicine for Healing
Depression is the most common reason people quietly start Googling ayahuasca at 2 a.m. I've sat across from dozens of them in pre-retreat interviews — engineers, mothers, recovering addicts, retired teachers — and the story is almost always the same. They've tried the medications. They've tried therapy. Something still isn't moving. So they start reading about psychedelics, and the research they find is genuinely encouraging. Here's what's actually known about psychedelics and depression in 2026, what's still uncertain, and what to think about if you're weighing a retreat as part of your own path forward. The World Health Organization estimates more than 280 million people live with depression worldwide. It's the leading cause of disability on the planet. And despite five decades of SSRIs, talk therapy, and an ever-expanding menu of treatments, the global numbers keep climbing — not falling. For roughly a third of people diagnosed with major depression, the standard tools don't work well enough. That's treatment-resistant depression: you've tried two or more medications at adequate doses, and you're still struggling. It's a brutal place to be, and it's the population most psychedelic studies have focused on. Major depression — the form most relevant to plant-medicine work — usually shows up as some combination of persistent low mood, exhaustion, anhedonia (the loss of pleasure in things that used to matter), isolation, and intrusive thoughts that don't quit. If any of that sounds familiar, you're not alone in turning over every stone. The first wave of psychedelic research began in the 1950s, mostly around LSD. It produced promising results, then was cut short by the political crackdown of the late 1960s. The work picked back up in the 1990s, and the past decade in particular has produced a body of evidence serious enough that institutions like Johns Hopkins, NYU, and Imperial College London have built dedicated psychedelic research centers. Across that work, a consistent pattern has emerged. When given in a supportive setting — careful screening, trained facilitators, integration support afterward — psychedelics appear to produce rapid and often long-lasting reductions in depressive symptoms. Not in everyone. Not as a magic bullet. But in proportions that traditional psychiatry hasn't seen in decades. A few of the substances that keep coming up: Each works differently. Each carries different risks. None should be approached casually. If you've read a news article about psychedelics in the last few years, it was probably about psilocybin. That's because it has the cleanest research record so far. A landmark 2016 trial at Johns Hopkins found that a single high-dose psilocybin session, paired with therapy, produced substantial and sustained drops in depression and anxiety among patients with life-threatening cancer. Follow-ups years later showed many of those benefits had stuck. Then came the Imperial College work led by Robin Carhart-Harris. Two doses of psilocybin, in patients whose depression hadn't responded to anything else, brought relief that lasted up to six months. His team's brain-imaging research suggested psilocybin temporarily quiets the default mode network — the part of the brain that runs the same loops of self-referential, often self-critical thought that characterize depression. When that network goes quiet, parts of the brain that normally don't talk to each other start communicating. People describe it as something loosening. One detail worth knowing: the patients who reported what researchers call a “mystical experience” during their session — a sense of unity, awe, or contact with something larger than themselves — were the ones most likely to see depression lift. The chemistry alone doesn't seem to be enough. The experience matters. Ayahuasca has been used ceremonially by Indigenous Amazonian communities for centuries. Western science showed up late to the conversation — most rigorous studies are from the 1990s onward — but the findings have been striking. A 2018 Brazilian randomized placebo-controlled trial gave ayahuasca to people with treatment-resistant depression. A single session produced rapid antidepressant effects that were still measurable a week later. As with psilocybin, brain imaging pointed to changes in the default mode network. Participants weren't just feeling better; the actual wiring of their rumination loops seemed to soften. What I've watched in person at retreats matches the data, with caveats. People who come in carrying years of depression often describe the ceremony as the first time in a long while they've felt something other than the weight. Not euphoria — more like a deep recalibration. Some cry for hours. Some sit in silence and watch their whole life play back. Some throw up a lot (the purge is a real and unglamorous part of the experience). Most report, in the weeks after, that the constant background noise of depression has gotten quieter. But ayahuasca is not gentle. It's a full-body, multi-hour journey. People with certain conditions — bipolar disorder, schizophrenia, a family history of psychosis, certain heart conditions, and anyone on SSRIs or MAOIs without proper medical tapering — should not drink it. A reputable retreat will screen carefully and turn people away. A bad one won't. Microdosing — taking sub-perceptual doses of LSD or psilocybin every few days — has become its own cottage industry. The anecdotal reports are everywhere: better mood, more focus, lifted depression, more emotional availability. The peer-reviewed research is more mixed. Several recent studies have suggested microdosing may produce real benefits, while others have found the effects are largely placebo. My honest read: microdosing might help some people some of the time, but it's not the same intervention as a full psychedelic-assisted session. The breakthroughs people describe from a single guided ayahuasca or psilocybin experience aren't typically what microdosers report. If your depression is severe, microdosing is unlikely to be the answer. If you're managing a mild rut and want to experiment carefully and legally, that's a different conversation. If you're considering plant medicine specifically because depression is grinding you down, here are the things I'd want you to know before booking anything. Psychedelics are not for everyone. People with bipolar disorder or a personal or family history of psychotic illness are excluded from research trials for good reason — the medicine can destabilize those conditions, sometimes severely. Pregnant women, people with significant cardiovascular disease, and anyone in acute crisis should not be drinking ayahuasca at a retreat in the jungle. Legality also matters. Ayahuasca exists in a gray zone in most countries; psilocybin therapy is becoming legal in specific jurisdictions (Oregon and Colorado in the U.S., for example), but recreational possession remains illegal almost everywhere. Many of the most-respected retreats operate in countries where the medicine is legal or culturally protected — Peru, Costa Rica, Brazil, the Netherlands, Mexico, Jamaica. And the research itself, while genuinely promising, is still young. We have strong signals, not final answers. A serious facilitator will tell you that. A salesperson won't. If you're depressed and reading this, the fact that the science is finally catching up to what Indigenous communities have known for centuries is, on balance, good news. Psychedelics aren't a shortcut around the hard work of recovery — they're a tool that, used with care, can crack open doors that have been welded shut for years. The decision to attend a retreat is personal, medical, and worth making slowly. Talk to your doctor. Talk to people who've done it. Read the trial results yourself. Trust your own pace. If something here speaks to you, the available psychedelic and plant-medicine retreats discussed throughout this piece can be browsed on our marketplace here — quietly, on your own time, with no pressure to do anything except keep learning.
Craving More Stories?
Join our ShopAyahuascaRetreats newsletter for the latest updates on thrilling
destinations and inspirational tales, delivered straight to your inbox!
We value your privacy. Your email address will never be shared or published.
Psilocybin for Depression: What a Year-Long Johns Hopkins Study Actually Found
Picture this: two psilocybin sessions, spaced a couple of weeks apart, and a year later your depression scores are still down. That's the finding making the rounds out of Johns Hopkins, and if you're someone quietly considering a psychedelic retreat for a low mood that won't lift, it's worth understanding what the research actually says — and what it carefully avoids saying. The short version is genuinely promising. The longer version, which is the one you need if you're weighing a real decision, comes with caveats that the cleaner headlines tend to skip. Let's go through both. Researchers at the Johns Hopkins Center for Psychedelic and Consciousness Research followed 24 adults with major depressive disorder after giving them two doses of psilocybin alongside supportive psychotherapy. They'd already published earlier results showing the antidepressant effect held for two months. The new paper, in the Journal of Psychopharmacology, extends that follow-up to a full twelve. The numbers are striking. Average depression scores dropped from 22.8 — squarely in the severe range — to 7.7, which sits right at the threshold of no depression at all. That's not a marginal nudge. That's the kind of shift people normally chase across years of medication trials, talk therapy, and dose adjustments. And the participants got there with two guided sessions. No serious adverse events were reported as related to the psilocybin itself. Roland Griffiths, who led the work, framed it bluntly: where standard antidepressants need to be taken every day, often indefinitely, psilocybin may be able to do the job with one or two carefully held sessions. That's a different model of treatment entirely. Depression rarely travels alone. People who land on the idea of psychedelics — ayahuasca, psilocybin, ibogaine, San Pedro, the broader family of master plants — are often dealing with some braided combination of low mood, anxiety, trauma, and addiction. The same neural ruts that keep someone reaching for a drink at 9pm keep them reaching for the same dark thought at 3am. They're not separate problems wearing different costumes. That's part of why psychedelic-assisted recovery has caught so much attention. The effect isn't symptom suppression; it's something closer to a temporary loosening of the patterns themselves. Psilocybin appears to act on serotonin pathways in a way that interrupts the looping, self-referential negativity that defines a depressive episode. For some people, that interruption is enough to climb out. For others, it opens a window — and what they do with that window matters more than the medicine. This is the part the research gestures at but doesn't shout. About a third of the study's participants started an antidepressant during the follow-up year, and roughly 40% got some form of psychotherapy. The headline isn't psilocybin alone fixes depression for a year. The honest version is psilocybin, plus integration, plus often some combination of ongoing support, produced lasting change for most of the people in this small study. Not as snappy. More accurate. Standard SSRIs work for many people, partially work for many more, and don't work at all for a stubborn minority. Even when they help, they ask for daily commitment, side effects ranging from sexual dysfunction to emotional flattening, and a wind-down period that can be genuinely miserable. Psilocybin, in this trial, looks more like a procedure than a prescription — closer in shape to a surgical intervention than to a pill bottle. Two sessions. Substantial upfront cost in time, money, and emotional bandwidth. And then, in theory, you go on with your life. David Nutt of Imperial College London, who wasn't part of the Hopkins team, made the cost-efficacy point: the upfront expense of psychedelic therapy is high, but if the effects hold, it could compete with — or beat — the lifetime cost of conventional antidepressants. That math only works if the durability holds across larger and more diverse populations than 24 carefully screened volunteers, which is exactly what late-stage trials are now investigating. Here's where I want to slow you down, because this is where the gap between a research study and a real-world retreat opens widest. The Hopkins participants didn't take psilocybin on a beach in Jamaica or a jungle lodge in Peru. They took it in a controlled clinical room, with trained therapists, after multiple preparation sessions, with structured integration afterward. The medicine was one component of a careful protocol. Strip away the protocol and you're not running the same experiment anymore — you're running a different one, with different odds. A few things worth holding in mind if you're considering a psychedelic retreat for depression or addiction: None of this is meant to dampen the genuine promise here. It's meant to put the promise in scale. Psilocybin and the broader family of plant medicines look more and more like serious tools for serious problems. Tools, though. Not magic. The person holding the tool — meaning you, the support team, the facilitator, the therapist you see afterward — still does most of the work. The Hopkins paper sits inside a much larger wave. Compass Pathways is running late-stage psilocybin trials. MDMA for PTSD has been through multi-site Phase 3 work. Ibogaine continues to draw attention for opioid dependence. Ayahuasca research, slower and messier because of the ritual context, keeps producing intriguing signals around depression, addiction, and trauma. The picture forming across all of it is consistent: when paired with thoughtful psychological support, psychedelics can produce changes that standard pharmacology has struggled to match. The catch — and there's always a catch — is that the research settings bear little resemblance to most real-world settings. Underground use, casual recreational use, and even some retreat experiences strip away the elements that the trials suggest matter most. The medicine alone is not the whole story. It might not even be the most important part of the story. If you're someone reading this with a specific decision in mind — should I book a retreat, should I try psilocybin, should I look into ayahuasca for the thing I haven't been able to shake — let the research inform you without letting the headlines stampede you. The data is encouraging. The framework around the data is what makes it work. For readers who want to take this further, a range of carefully vetted psilocybin and plant-medicine retreats can be browsed on our marketplace here. Depression is patient. It waits. The good news is that the tools available for working with it are finally getting more interesting than they've been in decades. The better news is that you get to be deliberate about how you use them.
The DEA's Ayahuasca Risk Report: What It Says and Why It Matters
For years, anyone trying to understand how the U.S. government actually thinks about ayahuasca ran into the same wall. Lots of seizures at the border. Lots of denied religious exemptions. Very little paperwork explaining the reasoning. Then, in early 2023, a single document slipped out — a Drug Enforcement Administration report titled Ayahuasca: Risks to Public Health and Safety, dated July 2020. It surfaced only because a small church and a research nonprofit filed Freedom of Information Act requests and waited two years for a response that, by law, should have arrived in weeks. If you're researching an ayahuasca retreat — or wondering whether the brew might one day be regulated more like cannabis than like heroin — this document matters. It's the closest thing we have to an official federal position. And honestly? It's not great. The reasoning is thin in places, conflates a few different things, and reads like it was written to justify a conclusion rather than reach one. Let's unpack what's actually in it, what it gets wrong, and why it still shapes the legal landscape for plant medicine in the United States. The backstory is brief but telling. The Church of the Eagle and the Condor, working alongside the Chacruna Institute, submitted FOIA requests to the DEA and the Department of Justice asking for every record the government holds on ayahuasca. The requests went unanswered for years — a quiet violation of federal transparency law that, in fairness, is depressingly common when psychedelics are involved. When the DEA finally responded, it released exactly one document. That document had already been quietly cited in a 2021 denial letter rejecting another church's bid for a religious-use exemption. So the same report that no member of the public had read was being used to deny religious freedom claims. That's a striking detail. The government's entire articulated position on ayahuasca risk fits in a handful of pages, and until recently nobody outside the agency had seen the reasoning. This matters because ayahuasca occupies a strange legal corner. The brew itself isn't scheduled — DMT, one of its components, is. Two religious groups (the União do Vegetal and Santo Daime) have won Supreme Court and federal court protection to use it as a sacrament. Every other group seeking that same protection has to argue from scratch, and the DEA's risk assessment is now part of what they're arguing against. The report's headline conclusion is that ayahuasca poses a risk to public health and safety. To reach that, it leans on a few main arguments — and this is where the reasoning gets wobbly. First, the document repeatedly treats ayahuasca and pure synthetic DMT as if they were interchangeable. They aren't. Ayahuasca is a brewed decoction of two plants — usually Banisteriopsis caapi and Psychotria viridis — that produces a long, oral experience moderated by MAO inhibitors in the vine. Smoked or injected DMT is a brief, intense flash with a completely different pharmacological profile. Conflating them is roughly like writing a risk assessment of beer by citing data on grain alcohol. The substances overlap, but they don't behave the same way in the body, in ceremony, or in the data. Second, the assessment catalogs adverse events without much context. Vomiting and diarrhea are listed as concerns. Anyone who has sat in a ceremony will tell you these are not side effects in the conventional sense — they're part of how the medicine is traditionally understood to work. The term la purga exists for a reason. That doesn't mean the discomfort is trivial, but framing it as evidence of public-health danger is a bit like calling a sauna unsafe because people sweat. Third, the report leans on case reports of psychiatric crises and a handful of deaths. These do happen and shouldn't be brushed aside. But the document doesn't weigh them against base rates, doesn't account for whether the participants had medical or psychiatric contraindications that responsible screening would catch, and doesn't compare the risk profile to substances the same agency considers acceptable. Here's what the report doesn't do, and the gaps are arguably more important than what it does include. None of this means the DEA was obligated to declare ayahuasca safe. It does mean the document reads less like a balanced scientific review and more like a brief written for one side of an argument. You might reasonably ask: how does a federal report I'll never read affect my decision about whether to fly to Peru or Costa Rica and sit in ceremony? More than you'd think. The U.S. government's position drives a lot of downstream consequences. Customs and Border Protection seizures of ayahuasca have increased noticeably in the last few years. Practitioners have been arrested. New religious groups seeking the same legal protection as the UDV and Santo Daime are being denied based on reasoning that traces back, in part, to this very document. If you've ever wondered why your friend's facilitator suddenly stopped doing ceremonies in the U.S. and now runs them in Mexico, this is part of the answer. For the practical retreat-goer, a few takeaways. Drinking ayahuasca in countries where it's legal — Peru, Brazil, Costa Rica, the Netherlands, and others — sidesteps the U.S. legal question entirely while you're abroad. Bringing brew back into the States is a different matter, and not one I'd recommend testing. And if you're attending a U.S.-based ceremony, it's worth knowing the legal posture of the group hosting it. Some operate under recognized religious exemptions. Many don't, and the risk profile is real, both for facilitators and, occasionally, participants. The most damning thing about the FOIA episode isn't the report itself. It's that the government sat on these records for two years, in violation of its own transparency obligations, while citing the unreleased document to deny religious freedom claims. That's not how administrative law is supposed to work. Decisions affecting fundamental rights are supposed to be made on a record the affected parties can see and contest. The good news is that the document is now public, which means it can be critiqued, rebutted, and — eventually — replaced by something better. Advocacy groups are actively pushing for a more honest federal conversation about ayahuasca, one that distinguishes plant medicine from isolated compounds, weighs benefits alongside risks, and respects the diversity of traditions that have safely used the brew for generations. For now, if you're weighing whether plant medicine has a place in your own life, the most useful thing you can do is get specific. Read the actual research, not the headlines. Talk to people who have done the work — both the ceremony and the integration afterward. Ask hard questions of any retreat you're considering: who screens for contraindications, what medications conflict with the brew, what their aftercare actually involves. The federal posture is what it is, but your decision is yours. If something in this piece resonated and you want to look at what's actually out there, a curated selection of ayahuasca retreats can be browsed on our marketplace here. Pick the place carefully, prepare seriously, and treat the experience with the respect it asks for.
Types of Psychedelic Mushrooms: A Field Guide to Psilocybin Species and Fly Agaric
Walk into any conversation about psychedelics long enough and someone will say the word “mushrooms” as if it refers to a single thing. It doesn't. The world of psychedelic mushrooms is wider, weirder, and more geographically scattered than most people realize — over 180 known species, several different genera, and at least two completely separate chemical mechanisms producing the trip. If you're researching plant medicine seriously, or considering a psilocybin retreat, knowing what's actually inside the cap matters. This guide walks through the main families of psychedelic mushrooms, what makes them chemically distinct, and why the iconic red-and-white Amanita muscaria is its own strange beast — related to the others mostly in shape, not in spirit. A psychedelic mushroom is any fungus that contains a compound capable of meaningfully shifting perception, mood, or cognition. The vast majority owe their effects to psilocybin — a prodrug that the body quickly converts into psilocin, the actually-active molecule. Psilocin slots into serotonin receptors in the brain (the 5-HT2A site, mostly), and that's where the visuals, the time dilation, and the rearranging of inner furniture come from. People have been eating these mushrooms for a long time. Cave murals in Spain dating back roughly 6,000 years appear to depict Psilocybe hispanica. Desert rock art in Algeria, older still, suggests mushroom use stretching back seven to nine millennia. The Maya consumed Psilocybe cubensis. The Aztecs called certain species teonanácatl — “flesh of the gods.” Whatever you make of that lineage, mushrooms have arguably the longest documented relationship with humans of any psychedelic. The Swiss chemist Albert Hofmann — the same person who first synthesized LSD — isolated psilocybin and psilocin from Psilocybe mexicana in the late 1950s. That moment basically opened the modern scientific chapter on these fungi. Everything since, including the current clinical trials on psilocybin for depression, end-of-life anxiety, and addiction, traces back to that little Mexican mushroom. Most psychedelic mushrooms people will encounter — at a ceremony, at a retreat, in a research paper — belong to the genus Psilocybe. It's the largest grouping, with around 117 species, and contains nearly all the famous names. A few worth knowing: You'll also see Psilocybe baeocystis (bottle caps), Psilocybe pelliculosa, and Psilocybe aztecorum, the latter possibly being one of the original teonanácatl species. Each has its own potency profile, its own habitat, and its own enthusiasts. Psilocybe gets the spotlight, but psilocybin shows up in roughly a dozen other genera. The chemistry is the same — psilocybin, psilocin, sometimes baeocystin — but the mushrooms look and grow differently. Panaeolus is probably the most notable runner-up. Panaeolus cyanescens (sometimes called Copelandia cyanescens, or just “blue meanies”) is significantly more potent than your average cubensis. It's a tropical and subtropical mushroom, common in cattle pasture across Hawaii, parts of Mexico, and Southeast Asia. Panaeolus cinctulus — the banded mottlegill — is less potent but more widely distributed. Other genera include Gymnopilus, Pluteus, Inocybe, Hypholoma, and a handful of less common groupings. Inocybe aeruginascens deserves a quick mention because it's one of only two known natural sources of aeruginascin, a compound that some researchers have informally called “the CBD of magic mushrooms” for its apparent ability to soften the rougher edges of a trip. Whether that holds up under proper clinical scrutiny is still an open question. The point isn't that you need to memorize all this. The point is that “magic mushrooms” isn't a single substance — it's a category that includes everything from the laboratory-bred Penis Envy to obscure species growing on rotting logs in northern Spain. And then there's Amanita muscaria. The red cap with white dots. The mushroom in every video game, fairy tale, and Mario world. It is psychoactive — but it is not a psilocybin mushroom, and lumping it in with the others is a category error worth correcting. Amanita muscaria belongs to a genus that includes some of the most toxic fungi on Earth. The Amanitas as a group are responsible for the overwhelming majority of fatal mushroom poisonings worldwide. Fly agaric itself is technically classed as poisonous, though actual deaths from it are vanishingly rare and almost always involve massive overdoses or confusion with a more dangerous relative. The active compounds in fly agaric are muscimol and ibotenic acid, with smaller amounts of muscazone and muscarine. When you eat the mushroom, your body converts ibotenic acid into muscimol — the more potent of the two. Crucially, muscimol doesn't touch serotonin receptors at all. It acts on the GABA system, which is roughly the brain's brake pedal. That's why an Amanita experience is described so differently from a psilocybin one: less kaleidoscopic, more dreamlike, often sedating, sometimes outright dissociative. Effects can include: Indigenous shamans across Siberia — particularly the Koryak and Evenki peoples — have used fly agaric ritually for centuries, sometimes consuming it directly, sometimes drinking the urine of someone who already had (muscimol passes through the body largely intact, which is grim but pharmacologically interesting). It is, in every meaningful sense, a different medicine than psilocybin. If you're considering a retreat or ceremony, the practical question isn't usually “which species?” — most legitimate facilitators are working with Psilocybe cubensis or Psilocybe tampanensis truffles, and that's a known, well-mapped experience. The more useful questions are about dose, setting, screening, and integration support. A few things genuinely worth asking before you commit: The fly agaric question is a different conversation. Amanita muscaria retreats exist, but they're rarer, less standardized, and worth approaching with extra caution. The compound profile is genuinely different and the experience can be physically rougher. It's not for first-timers. One thing that gets lost in the listicle-style coverage of psychedelic mushrooms: these are old organisms with old relationships to people. The species names matter less than the relationship you build with whichever one you sit with. Curiosity is good. Reverence is better. A bit of fear, in the proper sense — taking the thing seriously — is probably the most underrated ingredient in a good psychedelic experience. For readers who want to take this further, a range of curated psilocybin and plant-medicine retreats can be browsed on our marketplace here. Whichever direction you go, the mushroom you choose deserves the same care you'd give any teacher worth the name.
Ibogaine for Addiction Recovery: What Families Need to Know Before Booking
Somewhere in the world right now, a mother is sitting at her kitchen table reading message-board threads at 2 a.m., trying to decide whether to send her son to a clinic in Mexico because nothing else has worked. That's the real audience for any honest conversation about ibogaine. Not the wellness-curious. Not the psychonauts collecting experiences. The families and individuals who have run out of options and are weighing a plant medicine most of their doctors have never heard of. Ibogaine sits in a strange category. It's one of the most studied psychedelics for addiction recovery, and simultaneously one of the least talked about in mainstream coverage of plant medicines. People who go through it tend to describe it less as a trip and more as a reckoning. So before anyone clicks the booking button, here's what's actually worth understanding. Ibogaine is the principal alkaloid in the root bark of Tabernanthe iboga, a small shrub native to the forests of Gabon and surrounding countries in west-central Africa. The Bwiti tradition has used iboga ceremonially for generations — for initiation, for ancestral connection, for healing crises that families can't solve on their own. The plant landed on Western radar in the 1960s when a young heroin user named Howard Lotsof took it recreationally and noticed, to his shock, that his withdrawal symptoms had vanished. The story of modern ibogaine treatment starts there. Pharmacologically, ibogaine is unusual. It interacts with multiple receptor systems at once — opioid, serotonin, NMDA, sigma — and its metabolite noribogaine lingers in the body for days. The practical effect, for someone in active opioid dependence, is often a near-complete interruption of withdrawal. That's not marketing language. That's what study participants and clinic data have repeatedly described. Whether the underlying craving stays gone is a separate question, and that's where retreats, integration, and aftercare matter more than the molecule itself. If you've been researching plant medicine for addiction, you've probably bumped into ayahuasca and psilocybin as well. They're not interchangeable. Ayahuasca tends to work through emotional and visionary processing — people often describe confronting memories, family patterns, the roots of why they started using. A psilocybin retreat can do something similar, with a gentler pharmacology and a shorter session. Ibogaine is different in one specific way: it appears to physically reset the opioid receptor system. People come off heroin, fentanyl, oxycodone, and methadone with their withdrawal flattened in ways that other psychedelics don't replicate. Anecdotally, it also helps with stimulant dependence — cocaine, meth — though the mechanism there is murkier. For alcohol, the evidence is mixed and personal. None of these is a magic bullet. The people who do best with any of them tend to be the ones who treat the medicine as the start of the work, not the finish. Here's the part where I'd rather be blunt than reassuring. Ibogaine is the most cardiotoxic of the commonly used plant medicines. It prolongs the QT interval — a measurement of heart electrical timing — and in people with undiagnosed heart conditions, electrolyte imbalances, or certain medication interactions, that can be fatal. There have been deaths. Most have happened at underground or under-equipped settings where pre-screening was inadequate or where someone was still using opioids when they took the dose. What a reputable ibogaine clinic does, at minimum: If a place doesn't do those things — if they wave off the EKG, if there's no doctor, if they're casual about your medication list — walk away. I don't care how good the testimonials are. The medicine is too strong to gamble with. People expect a psychedelic light show. That's not really what ibogaine delivers. The acute experience usually starts an hour or two after dosing and unfolds in phases. The first phase is often called the visionary state — eyes closed, lying down, a stream of images and memories that participants frequently describe as watching their life back, sometimes from unusual angles. There's not much choice involved. The medicine shows you what it shows you. The middle hours can feel physically demanding. Nausea, ataxia, light and sound sensitivity, a heavy body. This is not a dance ceremony. You will be on a mat or in a bed, with a quiet attendant nearby, for most of a day. The introspective phase follows — quieter, more verbal-thought-like, the part where the lessons of the visionary phase get processed. Then a long, sleepless tail of 24 to 48 hours where the body slowly recalibrates and rest is hard to come by. Most people who've done ibogaine for opioid dependence say the same thing afterward: the cravings, the constant background hum of I need to use, is gone or radically diminished when they wake up on the other side. That window is the gift. What you do with it determines whether the recovery sticks. Ibogaine is famous for its post-treatment window — sometimes called the grey day phase — when people report feeling unusually clear, motivated, free of the obsessive pull they lived with for years. That window can last weeks or months. It is not permanent on its own. The receptors come back. The life circumstances that fed the addiction are still there. The relationships, the job, the trauma underneath, the friends who still use — none of that got touched by the molecule. This is the place where so many ibogaine stories take a heartbreaking turn. Someone comes home from a clinic clear-headed, doesn't build the scaffolding (therapy, peer support, a new daily structure, a way to handle the first hard week), and within a few months they're back where they started, sometimes worse. Tolerance drops dramatically after ibogaine, which makes a relapse with the same old dose genuinely dangerous. If you or someone you love is considering this, the question to ask the clinic is not just how is the dosing session? It's what happens for the six months after I leave? Good programs will have an answer. They'll connect you to integration therapists, sometimes to follow-up booster sessions with a lighter medicine like 5-MeO-DMT or microdoses of iboga, sometimes to peer communities. If the answer is essentially you're on your own, treat that as a red flag. Ibogaine isn't for everyone who's struggling. People with a history of significant heart disease, long QT syndrome, recent cardiac events, untreated mental health conditions like active psychosis or bipolar I, or who can't get fully off long-acting opioids beforehand — these are situations where the risk-benefit math doesn't work, no matter how desperate things feel. A good clinic will turn applicants away. That's not them being difficult. That's them keeping you alive. For people who don't fit the ibogaine profile, other plant medicines or clinical pathways may be a better starting point. Sometimes the right move is a psilocybin retreat first, or trauma-focused therapy, or medication-assisted treatment to stabilize before considering anything else. The goal is recovery, not which substance gets credit for it. If you've read this far, you're probably not looking for permission. You're looking for clarity. So here's the honest summary: ibogaine is a serious medicine with a real track record in addiction recovery, particularly opioid dependence, and a real risk profile that demands medical screening and a structured environment. The people it helps tend to be the ones who do their homework, choose a clinic with proper safety standards, and commit to the integration work afterward. The people who get hurt are usually the ones who skipped one of those steps. Talk to people who've been through it. Read accounts that include the difficult parts, not just the success stories. Ask hard questions of any retreat you're considering. And if it feels right after all of that, the curated ibogaine and plant-medicine retreats discussed across the broader recovery space can be browsed on our marketplace here. Whatever you decide, the willingness to look this clearly at the choices in front of you is already part of the work.
How to Be a Good Trip Sitter: A Practical Guide to Holding Space During Psychedelics
The first time a friend asked me to sit for them while they took mushrooms, I said yes before I really understood what I was agreeing to. I figured I'd hang out, keep an eye on things, maybe pour some water. What I didn't realise — and what most people don't, until they're four hours in watching someone weep at the ceiling — is that trip sitting is a real role with real responsibilities. It's not babysitting. It's not therapy. And it's definitely not a chance to micro-dose alongside your friend for moral support. If you're considering sitting for someone on a psychedelic — mushrooms, LSD, MDMA, ketamine, or anything in between — this is the honest version of what the job actually looks like. I'll also touch on where home trip sitting ends and where a proper plant-medicine retreat begins, because the two are very different animals. A trip sitter is a sober, trusted person who stays present while someone else journeys on a psychedelic substance. Their job is not to guide the experience, interpret visions, or play shaman. Their job is to make sure the person tripping stays physically safe, emotionally supported when needed, and otherwise left alone to have their own experience. Think of a sitter as a quiet lifeguard. Most of the shift, nothing dramatic happens. You sit nearby, read a book, refill a glass of water, occasionally check that your friend hasn't decided to redecorate the kitchen at 3am. The value isn't in constant intervention — it's in the simple fact of being there. Many people describe feeling enormous relief just knowing someone calm is in the next room. One thing worth saying upfront: a trip sitter isn't mandatory. Plenty of experienced psychonauts journey alone and do fine. But for first-timers, for higher doses, or for anyone with a complicated relationship to anxiety, having a sitter can be the difference between a difficult patch and a genuinely scary one. This part trips people up. A sitter is not: If your friend needs the kind of structured, ceremonial holding that plant medicine traditions provide, a retreat is the right environment — not your living room. Knowing the difference is part of being a responsible sitter. Preparation is where most sitters underinvest. The actual sitting is mostly waiting; the prep is where the real work lives. Start with the substance. A mushroom journey runs roughly four to six hours. LSD can stretch past twelve. MDMA peaks fast and tapers. Ketamine is much shorter but more dissociative. If you don't know what's normal for the molecule in question, read up — Wikipedia is a reasonable starting point for pharmacology basics, but go deeper from there. You should know roughly when the come-up starts, when the peak hits, and when things should be tapering off. Then get to know the person, if you don't already. What are they hoping to explore? Are they working through something heavy — grief, a breakup, addiction recovery, an old trauma? Have they done psychedelics before, and if so, how did it go? Are they on any medications, especially SSRIs or anything that interacts dangerously with what they're about to take? This last point isn't optional. Combining MDMA with certain antidepressants can cause serotonin syndrome, which is a medical emergency. Finally, prepare the setting. Set and setting aren't just buzzwords — they shape the whole experience. The room should be comfortable, dim-ish, free of obvious hazards (no open flames, no easy access to balconies or stairs, no sharp clutter), and stocked with water, soft blankets, a sick bowl if the substance tends to bring nausea, and a phone in case you need help. Music is often welcome but should be discussed in advance; what sounds like a gentle piano track sober can sound like a horror soundtrack at hour three. Here's the truth most guides bury: a good trip sitter is mostly bored. That's the sign you're doing it right. Stay close but not in their face. Read. Knit. Stare at a wall. Do not scroll loud videos on your phone. Do not invite other people over. Do not start a deep conversation about politics. Your job is to be a calm, low-stimulus presence — not entertainment. Check in occasionally, but lightly. A soft “how are you doing?” every so often is plenty. If they want to talk, listen without steering. If they want silence, give them silence. If they get up to move around, follow at a distance — falls and stubbed toes are a real risk when depth perception is scrambled. When things get hard — and on a meaningful dose, they often will at some point — your tools are simpler than you'd think: And the hardest skill: knowing when to back off. Some people in difficult passages don't want to be touched or talked to. Paranoia can latch onto the sitter. If your presence is making things worse, give them space — stay in earshot, but stop trying to fix it. The discomfort often needs to move through them, not be argued away. If you ever see signs of a true emergency — chest pain, seizure, sustained violent behaviour, genuine suicidal intent, signs of serotonin syndrome — call emergency services without hesitation. Tell them exactly what was taken. Honesty saves lives in those moments, and medics are not there to get anyone arrested. The trip doesn't end when the visuals fade. The hours and days afterward are when the real work of integration begins, and a good sitter understands this. Once your friend is back in their body, feed them. Something simple — fruit, toast, soup. Hydrate them. Let them sleep if they need to. The next morning, when they're rested, sit with them and let them talk about what came up. Don't interpret. Don't analyse. Just listen and reflect back what they say. Sometimes the most important moment of the whole experience happens at breakfast the next day, over a slow cup of coffee, when something they saw finally clicks into a sentence. If the experience was hard, don't paper over it. Difficult trips often carry the most useful material if they're processed honestly. Encourage journaling, gentle walks, time in nature. If real distress lingers more than a few days, point them toward a therapist who's familiar with psychedelic integration — they exist, and there are more of them every year. Trip sitting at home works well for recreational doses with experienced friends, or for someone doing careful personal exploration. It does not work well for everyone, and it's worth being honest about the limits. If someone is using psychedelics to work on serious trauma, deep depression, or addiction, a living-room setup is usually the wrong container. The traditional plant medicines — ayahuasca, ibogaine, peyote, San Pedro, psilocybin in ceremonial contexts — have been used for centuries inside structures specifically designed to hold the weight of that kind of work. Trained facilitators, dietary preparation, ritual framing, medical screening, and proper integration support all do real things that a friend with a thermos of tea cannot replicate. For readers weighing that bigger step, a curated range of ayahuasca and plant-medicine retreats can be browsed on our marketplace here. Trip sitting is a small act of love. You're trading a night of your own life so someone else can do something that might genuinely change theirs. Take the role seriously, but don't let it intimidate you — most trips are gentle, most challenges are workable, and most people come out the other side grateful, articulate, and a little bit changed. And when it's your turn to lie on the couch and stare at the ceiling, you'll know exactly what kind of person you want sitting in the next room. Pay it forward when the time comes.
Dreaming of a Psychedelic Retreat?
We have the best deals and offers from thousands of organizers all over the world! Get them into your mailbox every week!
We value your privacy. Your email address will never be shared or published.
